Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

CHICAGO and SAN FRANCISCO, June 4, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 as a second- and third-line treatment in patients with metastatic breast cancer during the 2011 American Society of Clinical Oncology Meeting (ASCO).  NKTR-102, a next-generation topoisomerase I inhibitor, is Nektar's lead oncology drug candidate and is being evaluated in multiple cancer indications.  The randomized Simon two-stage study presented at ASCO evaluated two 145 mg/m2 dose schedules of single-agent NKTR-102, every two weeks (q14d) and every three weeks (q21d), in 70 metastatic breast cancer patients who failed a prior taxane therapy.  Eighty-nine percent (62/70) of patients in the study received a prior anthracycline/taxane with or without capecitabine.

More than one million women worldwide are diagnosed with breast cancer every year and the disease is the leading cause of cancer-related death among women.(1)  

A total of 66 of the 70 patients treated with single-agent NKTR-102 in the Phase 2 study were assessable for the primary endpoint of objective tumor response rate (ORR), including confirmed complete responses (CRs) and partial responses (PRs) per RECIST 1.0.  As of May 9, 2011, for the q14d day schedule, the confirmed and unconfirmed ORR was 35 percent (11/31) and the confirmed ORR was 32 percent (10/31), including two confirmed CRs.  Clinical benefit rate for the 31 evaluable patients in the q14d schedule was 42% (13/31) (defined as confirmed CR+ PR+ Stable Disease (SD) >6 mos).  For the q21d schedule, the confirmed and unconfirmed ORR was 31 percent (11/35) and the confirmed ORR was 26 percent (9/35).  Clinical benefit rate for the 35 evaluable patients in the q21d schedule was 49% (17/35).  Clinical benefit rate for t
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... LONDON , April 21, 2015 ... for Enterprise, having achieved dazzling export-led growth in ... London™ today celebrates its part in winning the ... International Trade, awarded to Oxford PharmaGenesis. As part ... London helps its clients bring new medicines to ...
(Date:4/21/2015)... -- This report analyzes the worldwide markets for Apheresis ... for Therapeutic Apheresis, and Equipment for Donor Apheresis. Global ... Plateletpheresis, and Others. The report provides separate comprehensive analytics ... Japan , Europe , ... Annual estimates and forecasts are provided for the period ...
(Date:4/21/2015)... -- Cardiologists at Henry Ford Hospital have implanted a device ... irregular heartbeat. With only handful of hospitals in ... able to add another option to its arsenal of tools ... ability to pump. "This is a first ... implant at a non-clinical trial site," says cardiologist Claudio ...
Breaking Medicine Technology:Queen's Award Crowns Achievements of Fast-growing London Consultancy 2Queen's Award Crowns Achievements of Fast-growing London Consultancy 3Queen's Award Crowns Achievements of Fast-growing London Consultancy 4Queen's Award Crowns Achievements of Fast-growing London Consultancy 5World Apheresis Equipment Industry 2World Apheresis Equipment Industry 3World Apheresis Equipment Industry 4World Apheresis Equipment Industry 5World Apheresis Equipment Industry 6World Apheresis Equipment Industry 7World Apheresis Equipment Industry 8World Apheresis Equipment Industry 9World Apheresis Equipment Industry 10World Apheresis Equipment Industry 11World Apheresis Equipment Industry 12World Apheresis Equipment Industry 13World Apheresis Equipment Industry 14World Apheresis Equipment Industry 15World Apheresis Equipment Industry 16World Apheresis Equipment Industry 17World Apheresis Equipment Industry 18World Apheresis Equipment Industry 19World Apheresis Equipment Industry 20World Apheresis Equipment Industry 21Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3
(Date:4/21/2015)... 21, 2015 Top medical tourism firm, ... for their ongoing commitment to providing superior patient experiences. ... provide patients with the best possible experience for a ... and body. , Executives at Ojas Aesthetic Clinic persistently ... of — nothing about you, without you — through ...
(Date:4/21/2015)... Texas (PRWEB) April 21, 2015 ... H1 2015” provides comparative analysis on the ... R&D pipelines by identifying new targets and ... Complete report with TOC is available @ ... also reviews key players involved in the ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Angelo’s FabriClean ... pick-up and delivery for clients that avail the area ... by Angelo’s is done with hi-tech equipments, making use ... customers. They use all natural, high pressure steam extraction ... as hand washing for area rugs made with delicate ...
(Date:4/21/2015)... 2015 Information is the best weapon in ... FACP, empowers patients and their families with knowledge about living ... and Cancer is the Answer" and new website . ... to guide patients from diagnosis through treatment and even death. ... in their treatment, at home and in the examination room. ...
(Date:4/21/2015)... NJ & New York, NY (PRWEB) April 21, ... leading global provider of advanced delivery technologies and ... products, today announced the launch of ADVASEPT™ Lock, ... safe and efficient delivery of injectable medications. Easily ... combining a safe, convenient and functional container closure ...
Breaking Medicine News(10 mins):Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2
... patients who smoke, INDIANAPOLIS, Aug. 29 ... Tobacco Control Center (CTCC), a,part of the Clarian ... guidelines, set by the U.S. Public Health Service ... the release of the PHS 2008 Clinical Practice,Guideline ...
... Company, a life,and health insurance company, today announced ... product, ConsecoLifeOptions. The policy,provides upside potential with downside ... policy that offers the,opportunity for long-term cash buildup ... can customize their coverage levels with eight riders,that ...
... Holiday,Stationstore at 2660 Eagan Woods Drive in the Saint Paul ... dollar a gallon on Wednesday, September,3, from 11 a.m. until ... National Convention, and the fleet of flexible fuel vehicles,General Motors ... a,15 gallon limit per flexible fuel vehicle., The event ...
... InterMune, Inc.,(Nasdaq: ITMN ) today announced that Daniel ... at the Thomas Weisel Partners,Healthcare Conference in Boston on ... access a live audio webcast of the presentation, investors ... relations page of InterMune,s,corporate website at http://www.intermune.com . ...
... Scientific obligation reduced from $250 to $19 million, ... BSX ) today announced that the U.S. District Court ... MDT ),unenforceable for inequitable conduct during the prosecution ... Office., A jury had previously found that certain ...
... [Los Angeles cosmetic surgeon], Dr. Joel Aronowitz, has respected experience ... Special consideration may be necessary for these patients, health and wellness. ... for after weight loss. , ... Los Angeles, CA ...
Cached Medicine News:Health News:Indiana Tobacco Prevention and Cessation Awards Grant to Clarian Tobacco Control Center 2Health News:Indiana Tobacco Prevention and Cessation Awards Grant to Clarian Tobacco Control Center 3Health News:ConsecoLifeOptions Launched by Conseco Insurance Company as New Universal Life Product 2Health News:An 'Unconventional' Fuel at an Unbelievable Price: Minnesota Station Cuts Cost of E85 by $1 Per Gallon 2Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: